Everything below concerns melanocortin. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-21. Numbers and descriptions here follow the published literature rather than marketing material.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
| Property | Value | Notes |
|---|---|---|
| Research code | PT-141 | Used in early literature before the generic name became common |
| Generic name | Bremelanotide | International nonproprietary name |
| Peptide class | Cyclic heptapeptide | Seven residues joined by a lactam bridge |
| Primary receptor | MC4R | Lower affinity reported at MC1R, MC3R and MC5R |
| Route studied clinically | Subcutaneous injection | Intranasal route was abandoned after pressor effects |
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
== Biography == In 1993, he immigrated to Canada. Prior to the formation of DVS Sciences. Dr. Baranov, a senior scientist at MDS SCIEX, was a key member of the research team that developed and promoted the Dynamic Reaction Cell®, which remains today at the pinnacle of quadrupole ICP-MS technology. In 2005, together with Scott D. Tanner and Dmitry Bandura, he began independently developing an ICP-TOF-MS based cytometer and became a researcher at the University of Toronto in March 2005. After securing ample funding by 2010 from various sources, including National Institutes of Health, Ontario Institute for Cancer Research (OICR), the Ministry of Research and Innovation, Ontario Centres of Excellence, Health Technology Exchange, and Genome Canada via the Ontario Genomics Institute, and venture capital from 5 AM Ventures, Vladimir and the DVS Sciences team successfully commercialized their technology, leading to the acquisition of DVS Sciences by Fluidigm in 2014 Baranov was a principal scientist at DVS Sciences (and then Fluidigm) developing instrumental concepts and algorithmics that advance the CyTOF® line of products. He also and played a fundamental role in the development of the MaxPar line of metal-labeling reagents until his retirement in 2019.
=== India === In the 1990s, India stopped its research in cold fusion at the Bhabha Atomic Research Centre because of the lack of consensus among mainstream scientists and the US denunciation of the research. Yet, in 2008, the National Institute of Advanced Studies recommended that the Indian government revive this research. Projects were commenced at Chennai's Indian Institute of Technology, the Bhabha Atomic Research Centre and the Indira Gandhi Centre for Atomic Research. However, there is still skepticism among scientists and, for all practical purposes, research has stalled since the 1990s. A special section in the Indian multidisciplinary journal Current Science published 33 cold fusion papers in 2015 by major cold fusion researchers including several Indian researchers. A Hyderabad-based startup, Hylenr Technologies, showcased the amplification of electrical energy into significantly more heat energy using the a LENR system. The startup is being guided by a former DRDO scientist, Padma Shri awardee, Dr. Prahlada Ramarao.
Cold traps (C in the figure) usually consist of two parts: The bottom is a large, thick round tube with ground-glass joints (B in the figure), and the second is a cap (A in the figure), also with ground-glass connections. The length of the tube is usually selected so that, when assembled, the total reached is about half the length of the tube.
=== Informants and holdouts === Also targeted were civilians suspected of being informants of the apartheid police. Alongside petrol bombs, necklacing became a favoured method of executing such suspects. In one early example known nationwide, a young woman in Duduza, Maki Skosana, was necklaced on 20 July 1985 at a funeral for a local activist; a television crew filmed a crowd of young men kicking and beating her, tearing her clothes off, dousing her in petrol, and then setting her alight while one man rammed a glass bottle into her vagina. Skosana was rumoured to be the girlfriend and co-conspirator of Joe Mamasela, a notorious askari who had killed several Duduza youths by hand grenade in an entrapment operation in June. In addition, though mass action had broad support during this period, there were frequently complaints that the reluctant were compelled to participate in stay-aways or boycotts by force or intimidation. Groups of COSAS supports were accused of "erecting barricades to prevent residents from going to work; attacking those who tried to do so; moving from school to school ordering students out of class; hurling stones and petrol bombs at policemen; attacking buses and taxis; digging trenches in the streets; destroying buildings; and assaulting members of rival organisations". There was also evidence that vigilante attacks were sometimes perpetrated on the basis of mere political or personal "grudges".
=== First aid === Pre-hospital care for lung barotrauma includes basic life support of maintaining adequate oxygenation and perfusion, assessment of airway, breathing and circulation, neurological assessment, and managing any immediate life-threatening conditions. High-flow oxygen up to 100% is considered appropriate for diving accidents. Large-bore venous access with isotonic fluid infusion is recommended to maintain blood pressure and pulse.
Sources: en.wikipedia.org
In computing, FLOPS (FLoating point Operations Per Second) is a measure of a computer's computing power. It is also common to see measurements of kilo, mega, giga, and teraFLOPS. It is also used to compare the performance of computers in practice.
where the creatinine and blood urea nitrogen concentrations are both in mg/dL. The albumin concentration is in g/dL. These MDRD equations are to be used only if the laboratory has NOT calibrated its serum creatinine measurements to isotope dilution mass spectrometry (IDMS). When IDMS-calibrated serum creatinine is used (which is about 6% lower), the above equations should be multiplied by 175/186 or by 0.94086. Since these formulae do not adjust for body size, results are given in units of mL/min per 1.73 m2, 1.73 m2 being the estimated body surface area of an adult with a mass of 63 kg and a height of 1.7 m.
== Environmental record == According to the 2022 "Top 100 Polluters Indexes" published by the University of Massachusetts, Amherst's "Political Economy Research Institute" (PERI), BASF was ranked the #2 largest polluter of air and #14 largest polluter of water in 2020, the most recent year for which data is available from the U.S. Environmental Protection Agency. In 2006, BASF was included in the Climate Leadership Index for their efforts in relation to climate change and greenhouse gas emissions. The BASF Company and Columbia University formed a partnership to further research "environmentally benign and sustainable energy sources". The company has recently reported their emissions in 2006 to be "1.50 million metric tons of waste," which is a decrease from previous years. The amount of waste BASF produces has continued to fall. While BASF publishes its environmental information in the US and Europe, Greenpeace has expressed deep concerns at BASF's refusal to release environmental information on its operations in China. In May 2009, a BASF Plant in Hannibal, Missouri, United States, accidentally discharged chromium into the Mississippi River. The local Department of Natural Resources performed tests in December 2009 showing the chromium levels did not exceed regulatory safety limits. BASF worked with the Missouri Department of Natural Resources (MoDNR) to resolve questions regarding the elevated level of hexavalent chromium that was detected in the effluent from one of its permitted outfalls into the Mississippi River.
=== Troponin === In both cardiac and skeletal muscles, muscular force production is controlled primarily by changes in the intracellular calcium concentration. In general, when calcium rises, the muscles contract and, when calcium falls, the muscles relax. Troponin, along with actin and tropomyosin, is the protein complex to which calcium binds to trigger the production of muscular force.
PKU is an autosomal recessive metabolic genetic disorder. As such, two PKU alleles are required for an individual to experience symptoms of the disease. For a child to inherit PKU, both parents must have and pass on the defective gene. If both parents are carriers for PKU, any child they have will have a 25% chance to be born with the disorder, a 50% chance the child will be a carrier, and a 25% chance the child will neither develop nor be a carrier for the disease. PKU is characterized by homozygous or compound heterozygous mutations in the gene for the hepatic enzyme phenylalanine hydroxylase (PAH), rendering it nonfunctional. This enzyme is necessary to metabolize the amino acid phenylalanine (Phe) to the amino acid tyrosine. When PAH activity is reduced, Phe accumulates and is converted into phenylpyruvate (also known as phenylketone), which can be detected in the urine. Carriers of a single PKU allele do not exhibit symptoms of the disease, but appear to be protected to some extent against the fungal toxin ochratoxin A. Louis Woolf suggested that this accounted for the persistence of the allele in certain populations, in that it confers a selective advantage—in other words, being a heterozygote is advantageous. The gene for PAH is located on chromosome 12 in the bands 12q22-q24.2. As of 2000, around 400 disease-causing mutations had been found in the PAH gene. This is an example of allelic genetic heterogeneity.
Sources: en.wikipedia.org
== Nervous control == The mechanical states of catch connective tissue are under nervous control and thus we can regard this tissue as one of neurally controlled mechano-effectors such as muscles. It is found in the sea-urchin spine joints that the stiffness of catch connective tissue changes in the coordinated manner with the muscle contractions. One of the characteristic cells found in catch connective tissue is juxtaligamental cells containing secretory granules. These cells are supposed to contain proteins controlling stiffness of extracellular materials. When stained with the antibody specific to echinoderm nerves sea-cucumber body wall is supplied with immunoreactive fine fibers running among the collagen fibrils. Pharmacological experiments suggested the presence of two types of cholinergic systems, one is the nicotinic one involved in the dermal stiffening and the other is the muscarinic one involved in softening. Cholinergic nerves seem to control the secretory activities of juxtaligamental cells. The presence of the cholinergic system was supported by the neuropeptide stichopin that inhibits the action of stiffening cholinergic systems. Stichopin is one of four new peptides in the dermis of sea cucumbers. Other ones are the neuropeptide NGIWYamide that stiffens the dermis and two holokinins that soften the dermis. The nerves containing these neuropeptides possibly control the secretory activities of juxtaligamental cells.
=== Terminology === In 2021, a study in the UK showed that few are able to label the structure of the vulva correctly. There are many sexual slang terms used for the vulva. "Cunt", a medieval word for the vulva and once the standard term, has become a vulgarism, and in other uses one of the strongest offensive and abusive swear words in English-speaking cultures. The word has been replaced in normal usage by a few euphemisms including "pussy" (vulgar slang) and "fanny" (UK), which used to be a common pet name. In the UK, these terms have other non-sexual meanings that lend themselves to double entendres, such as "pussy", which is used as a term of endearment for a pet cat, "pussy cat". In North American informal use, the term "pussy" can also refer to a weak or effeminate man, and "fanny" is a term used for the buttocks. Other slang terms are "muff", "snatch", and "twat". "Vagina" is often incorrectly used as a synonym for vulva since it is separate from that anatomy.
Nearly 20,000 suspected armed OLF members, some of which were believed to be unarmed civilians (including children) were forcibly held in military camps in three different regions for the purpose of disarming and "re-educat[ing]" them, although very few had been released by the end of 1992. Throughout this time, the country's judiciary had failed to adequately adjudicate cases or to hold the TGE and its forces accountable for rights abuses. This was largely due to disruptions such as the looming threat of a possible suspension of all judges who were associated with the former Workers' Party of Ethiopia, the abrupt resignation of the Minister of Justice, a lack of an operating police force. These types of abuses persisted throughout the remainder of the transitional period. Freedom of the press was limited; in the first half of 1994, at least twenty journalists were fined or jailed as a result of publishing content that challenged the government, a situation exacerbated by the fact that the contemporary press laws were vague and improperly implemented. Human rights organizations including the Ethiopian Human Rights Council were denied formal registration from the government but continued to process complaints and report abuses; the government accused EHRCO of being a politically-motivated group with a hidden agenda that favored opposition groups and reported false information. Individuals suspected to have been previously associated with the OLF were treated particularly harshly once they were detained in secret detention centers across the country.
A U.S. court rejected the lawsuit blaming UCC for causing soil and water pollution around the site of the plant and ruled that responsibility for remedial measures or related claims rested with the State Government and not with UCC. In 2005, the state government invited various Indian architects to enter their "concept for development of a memorial complex for Bhopal gas tragedy victims at the site of Union Carbide". In 2011, a conference was held on the site, with participants from European universities which was aimed for the same.
Sources: en.wikipedia.org
The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.
MC4R is generally described as the principal target, based on binding affinity and functional assays. Activity at MC1R, MC3R and MC5R is reported as weaker. Receptor selectivity is one reason the compound was pursued for central rather than vascular effects.
Both are synthetic melanocortin analogues built on a similar cyclic peptide scaffold. Bremelanotide is described in the literature as a metabolite-derived analogue of melanotan II rather than the same substance. The two differ in terminal modifications, which affect half-life and receptor profile.
Reported activity is highest at MC4R, with lower potency at MC1R and MC3R. The MC4R interaction is generally treated as the most relevant to its central effects. Selectivity is not absolute, and activity across the family is dose-dependent.